.png)
Irish biotech company Nuritas, founded by Dr. Nora Khaldi, has raised $42 million in a Series C funding round to accelerate its mission of leveraging AI to uncover food ingredients that tackle global health challenges.
Nuritas, established in 2014, integrates IT and life sciences to mine plant DNA and protein data. Its focus is identifying rare bioactive molecules known as peptides, which hold immense potential for advancing human health. Dr Khaldi, a mathematician and bioinformatician, emphasized the company’s ambition to “improve the lives of billions” through innovative ingredients.
The company’s proprietary AI platform, Magnifier, can discover peptides 10–50 times faster than traditional methods. One of its flagship innovations, PeptiStrong, is derived from fava beans and supports muscle repair and generation. Validated by three human clinical trials, PeptiStrong has shown significant benefits, including enhanced strength, faster recovery, and sustained energy.
The funding round was led by M&G Investments, with participation from McWin Capital Partners, Grosvenor, and ECBF, as well as existing investors. The new capital will be directed toward scaling operations and expanding Nuritas’ global customer base.
Alex Seddon of M&G Investments and Henry McGovern of McWin Capital Partners will join Nuritas’ board of directors. Seddon expressed excitement about supporting Nuritas’ “groundbreaking work” in advancing health outcomes.
Nuritas has grown into a global biotech leader, earning accolades and significant investments over the years:
2016: Attracted celebrity investors Bono and The Edge.
2018: Secured €30M in funding from the European Investment Bank.
2019: Partnered with U.S. manufacturer Pharmavite.
2021: Raised $45M to expand into the U.S. and establish a new headquarters.
2022: Dr Khaldi was honoured with the Grace Hopper Award at the Diversity in Tech Awards.
Driving the Future of Health Through Science and AI
With its groundbreaking discoveries and cutting-edge platform, Nuritas continues to redefine the intersection of biotechnology, AI, and nutrition. The latest funding positions the company to further its mission of delivering sustainable, health-advancing solutions at scale.